Myocardial cell apoptosis reduction

Myocardial cell apoptosis reduction is not a discrete molecular target such as a receptor or enzyme; rather, it is a therapeutic objective or physiological process characterized by the mitigation of programmed cell death in cardiomyocytes. This process is highly relevant in the context of cardiovascular diseases, where the loss of cardiac muscle cells through apoptosis contributes significantly to ventricular remodeling, heart failure progression, and ischemia-reperfusion injury (PubMed: 10950821). Therapeutic interventions aim to achieve this reduction by modulating various molecular pathways, including the inhibition of cysteine-aspartic proteases (caspases), the stabilization of mitochondrial integrity, or the upregulation of anti-apoptotic proteins like Bcl-2 (NCBI: NBK507914). While many drugs, such as ACE inhibitors and beta-blockers, indirectly reduce myocardial apoptosis by decreasing wall stress and oxidative damage, experimental therapies specifically target the apoptotic machinery itself. Because this term refers to a biological outcome rather than a specific binding site for a drug, it is classified as a clinical or physiological end-point in drug development.

Other names

Cardiomyocyte apoptosis inhibitionReduction of myocardial cell deathMyocardial apoptosis preventionInhibition of programmed cell death in myocardium

Inhibition of pro-apoptotic signaling pathways (intrinsic and extrinsic), stabilization of mitochondrial membrane potential, and activation of pro-survival pathways such as PI3K/Akt/mTOR.